Subscribe for the newsletter
Sign in
Articles
Expert Interviews
Roundtable
Press Releases
Videos
The Road To Series
Market Research
Thought Leaders
More
Discovery
Small Molecules
Biologics
Advanced Therapies
Manufacturing
Supply Chain
Clinical Trials
Technologies
Financing
Juvenile Arthritis
Sort By
Newest First
1 / 1
1 / 1
FDA Approval
FDA Approves Subcutaneous Formulation of Actemra for Use in Active Polyarticular Juvenile Idiopathic Arthritis (PJIA), a Rare Form of Juvenile Arthritis
Genentech
PR-M05-18-NI-064
May 17, 2018
